skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8838

Agomelatine and its therapeutic potential in the depressed patient

(3092) Views  (838) Full article downloads

Authors: Sidney H Kennedy, Beata S Eisfeld

Published Date October 2007 Volume 2007:3(4) Pages 423 - 428
DOI: http://dx.doi.org/10.2147/NDT.S

Sidney H Kennedy, Beata S Eisfeld

University Health Network, University of Toronto, Canada

Abstract: Despite advances in understanding potential disease mechanisms and in developing novel therapeutic approaches to the treatment of major depressive disorder, the disease continues to carry an enormous personal, social, and economic burden. Agomelatine represents an important opportunity to advance the treatment of depression. It is a melatonergic (MT1 and MT2) agonist and serotonergic (5HT2C) antagonist. Evidence from animal models of depression, complements emerging clinical data. In a dose range of 25–50 mg daily, agomelatine is an effective antidepressant with a very favorable side-effect profile. In particular, sleep restorative action in the absence of sedation and minimal effect on sexual function suggests that agomelatine represents a worthwhile treatment alternative for patients with major depressive disorder.

Keywords: agomelatine, major depressive disorder, antidepressant, efficacy, tolerability








Readers of this article also read:

Levetiracetam in the treatment of childhood epilepsy
Effect of high-dose milnacipran in patients with depression
Intrathecal corticosteroids might slow Alzheimer’s disease progression
Agomelatine: The evidence for its place in the treatment of depression
Critical appraisal and update on the clinical utility of agomelatine, a melatonergic agonist, for the treatment of major depressive disease in adults
Retinal nerve fiber layer evaluation in multiple sclerosis with spectral domain optical coherence tomography
Retinal nerve fiber layer thickness in recovered and persistent amblyopia
Detection of retinal changes in Parkinson's disease with spectral-domain optical coherence tomography
Editorial
Improvement of adenoviral vector-mediated gene transfer to airway epithelia by folate-modified anionic liposomes